阿片类药物成瘾的药物研发：有意义的临床终点。
Medication development in opioid addiction: Meaningful clinical end points.
机构信息
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA.
Food and Drug Administration, Silver Spring, MD 20892, USA.
出版信息
Sci Transl Med. 2018 Mar 28;10(434). doi: 10.1126/scitranslmed.aan2595.
PMID:29593105
Abstract
The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
摘要
美国食品和药物管理局（FDA）批准新药物治疗阿片类药物使用障碍的“戒除”结果衡量标准一直难以实现；开发和验证替代有意义的结果可以促进药物开发。
Zotero 插件